Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 6/20 | 0.50 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.47 |
| ▸ | KDR known ✓ | P35968 | 7/20 | 0.46 |
| ▸ | CSF1R known ✓ | P07333 | 1/20 | 0.45 |
| ▸ | PDGFRB known ✓ | P09619 | 2/20 | 0.45 |
| ▸ | PDGFRA known ✓ | P16234 | 1/20 | 0.44 |
| ▸ | FLT1 known ✓ | P17948 | 1/20 | 0.44 |
| ▸ | LCK known ✓ | P06239 | 1/20 | 0.43 |
| ▸ | RET known ✓ | P07949 | 1/20 | 0.43 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.62 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.50 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | TNFSF11 | O14788 | 1/20 | 0.46 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KIF5B | P33176 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3427630 | 0.99 | ENPP1 (0.63) | ENPP1EGFRPDE10AACHEBACE1 | |
| SCHEMBL8777 | 0.99 | ENPP1 (0.63) | ENPP1EGFRPDE10AACHEBACE1 | |
| SCHEMBL1999978 | 0.93 | ENPP1 (0.54) | ENPP1EGFRPDE10AACHEBACE1 | |
| SCHEMBL3766549 | 0.89 | ENPP1 (0.52) | ENPP1EGFRPDE10AACHEBACE1 | |
| Hydrochloric Acid SCHEMBL3526531 | 0.87 | ENPP1 (0.79) | ENPP1EGFRKDRCSF1RPDGFRB | |
| SCHEMBL364049 | 0.85 | ENPP1 (0.81) | ENPP1EGFRKDRCSF1RFLT1 | |
| SCHEMBL29359187 | 0.85 | ENPP1 (0.81) | ENPP1EGFRKDRCSF1RFLT1 | |
| SCHEMBL3239272 | 0.85 | ENPP1 (0.68) | ENPP1EGFRPDGFRB | |
| Hydrochloric Acid SCHEMBL28016254 | 0.84 | PDE10A (0.51) | ENPP1EGFRPDE10AACHEBACE1 | |
| SCHEMBL17967514 | 0.84 | ENPP1 (0.59) | ENPP1EGFRPDE10AACHEBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021212536-A1 | METHOD FOR PREPARING 4-(3-CHLORO-4-FLUOROANILINE)-6-ACETOXY-7-METHOXY QUINAZOLINE HYDROCHLORIDE | 江苏天士力帝益药业有限公司 (CN) | 2021-10-28 | — | — | WO | claimed |
| CN-113549019-A | Preparation method of 4- (3-chloro-4-fluoroaniline) -6-acetoxyl-7-methoxyquinazoline hydrochloride | 江苏天士力帝益药业有限公司 | 2021-10-26 | — | — | CN | claimed |
| CN-105384699-B | A kind of novel quinazoline quinoline derivant LU1501 and its preparation method and application | 中国人民解放军南京军区南京总医院 | 2016-10-12 | — | — | CN | claimed |
| US-20230106731-A1 | INHIBITORS OF MUTANT FAMILY TYROSINE-KINASES | SPECTRUM PHARMACEUTICALS, INC. (US) | 2023-04-06 | — | — | US | disclosed |
| WO-2021212536-A1 | METHOD FOR PREPARING 4-(3-CHLORO-4-FLUOROANILINE)-6-ACETOXY-7-METHOXY QUINAZOLINE HYDROCHLORIDE | 江苏天士力帝益药业有限公司 (CN) | 2021-10-28 | — | — | WO | disclosed |
| WO-2021212536-A1 | METHOD FOR PREPARING 4-(3-CHLORO-4-FLUOROANILINE)-6-ACETOXY-7-METHOXY QUINAZOLINE HYDROCHLORIDE | 江苏天士力帝益药业有限公司 (CN) | 2021-10-28 | — | — | WO | disclosed |
| CN-113549019-A | Preparation method of 4- (3-chloro-4-fluoroaniline) -6-acetoxyl-7-methoxyquinazoline hydrochloride | 江苏天士力帝益药业有限公司 | 2021-10-26 | — | — | CN | disclosed |
| CN-113549019-A | Preparation method of 4- (3-chloro-4-fluoroaniline) -6-acetoxyl-7-methoxyquinazoline hydrochloride | 江苏天士力帝益药业有限公司 | 2021-10-26 | — | — | CN | disclosed |
| EP-3609875-B1 | AN IMPROVED PROCESS FOR THE PREPARATION OF N-(3-ETHYNYLPHENYL)-7-METHOXY-6-(3-MORPHOLINOPROPOXY) QUINAZOLIN -4-AMINE DIHYDROCHLORIDE | NATCO PHARMA LTD (IN) | 2021-10-20 | — | — | EP | disclosed |
| US-11091470-B2 | Process for the preparation of N-(3-ethynylphenyl)-7-methoxy-6-(3-morpholinopropoxy) quinazolin-4-amine dihydrochloride | NATCO PHARMA LIMITED (IN) | 2021-08-17 | — | — | US | disclosed |
| US-20200331899-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF N-(3-ETHYNYLPHENYL)-7-METHOXY-6-(3- MORPHOLINOPROPOXY) QUINAZOLIN -4-AMINE DIHYDROCHLORIDE | NATCO PHARMA LIMITED (IN) | 2020-10-22 | — | — | US | disclosed |
| WO-2001021596-A1 | QUINAZOLINE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | ASTRAZENECA AB (SE) | 2001-03-29 | — | — | WO | disclosed |
| EP-0823900-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-12-27 | — | — | EP | disclosed |
| WO-2000020402-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2000-04-13 | — | — | WO | disclosed |
| US-5866572-A | RECEPTOR TYROSINE KINASE INHIBITORY PROPERTIES, TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER. | ZENECA LIMITED (GB) | 1999-02-02 | — | — | US | disclosed |
| EP-0880507-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ZENECA LIMITED (GB) | 1998-12-02 | — | — | EP | disclosed |
| US-5770599-A | RECEPTOR TYROSINE KINASE INHIBITORS including 4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(2-morpholinoethoxy)quinazoline (gefitinib) | ZENECA LIMITED (GB) | 1998-06-23 | — | — | US | disclosed |
| EP-0823900-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1998-02-18 | — | — | EP | disclosed |
| WO-1997030034-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ZENECA LIMITED (GB) | 1997-08-21 | — | — | WO | disclosed |
| WO-1996033980-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230106731-A1 | INHIBITORS OF MUTANT FAMILY TYROSINE-KINASES | ERBB2, EGFR, ERBB3 | EGFR 2/4885ACHE 4802/4885KDR 31/4885 |
| US-11091470-B2 | Process for the preparation of N-(3-ethynylphenyl)-7-methoxy-6-(3-morpholinopropoxy) quinazolin-4-amine dihydrochloride | MAP7, NQO2, ABL1 | EGFR 2563/4885ACHE 1340/4885KDR 1760/4885 |
| US-20200331899-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF N-(3-ETHYNYLPHENYL)-7-METHOXY-6-(3- MORPHOLINOPROPOXY) QUINAZOLIN -4-AMINE DIHYDROCHLORIDE | PAH, NQO2, MAP7 | EGFR 2948/4885ACHE 1134/4885KDR 2909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.